Development and validation of a stability indicating HPLC method to determine diltiazem hydrochloride in tablets and compounded capsules
AUTOR(ES)
Souza, Mateus Araújo Castro e, Pereira, Carlos Eduardo de Oliveira, Nogueira, Fernando Henrique Andrade, Pianetti, Gerson Antônio
FONTE
Braz. J. Pharm. Sci.
DATA DE PUBLICAÇÃO
31/07/2017
RESUMO
ABSTRACT A stability indicating HPLC method to determine diltiazem hydrochloride (DTZ) in tablets and compounded capsules was developed and validated according to Brazilian and the International Conference on Harmonization (ICH) guidelines. The separation was carried out on a Purospher Star® C18 (150 x 4.6 mm i.d., 5 µm particle size, Merck Millipore) analytical column. The mobile phase consisted of a 0.05% (v/v) trifluoroacetic acid aqueous solution and a 0.05% trifluoroacetic acid methanolic solution (44:56, v/v). The flow rate was 1.0 mL.min-1 with a run time of 14 minutes. The detection of DTZ and degradation products (DP) was performed at 240 nm, using a diode array detector. The method proved to be linear, precise, accurate, selective, and robust, and was adequate for stability studies and routine quality control analyses of DTZ in tablets and compounded capsules.
Documentos Relacionados
- Development and validation of a stability-indicating HPLC method for the determination of buclizine hydrochloride in tablets and oral suspension and its application to dissolution studies
- Development and validation of a dissolution test for diltiazem hydrochloride in immediate release capsules
- Development and validation of a new and economical stability indicating RP-HPLC method for cefixime trihydrate
- Determination of cetirizine in tablets and compounded capsules: comparative study between CE and HPLC
- Stability indicating RP-HPLC method development and validation of cefepime and amikacin in pure and pharmaceutical dosage forms